KJ-C2320 / CARsgen - LARVOL DELTA

KJ-C2320: Targeting CD38, for the treatment of acute myeloid leukemia (AML). (Streetinsider.com) - "An IIT has been initiated at the end of 2024."

Trial status • Acute Myelogenous Leukemia

CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial (CARsgen Press Release) - "CARsgen Therapeutics Holdings Limited...announces that KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen’s THANK-uCAR platform. An investigator-initiated trial is ongoing in China to evaluate KJ-C2320 for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML)."

Trial status • Acute Myelogenous Leukemia